Bempedoic acid in secondary prevention

Authors

Idine Mousavi, Baylor College of Medicine, United States
Vijay Nambi, Baylor College of Medicine, United States
Layla A. Abushamat, Baylor College of Medicine, United States
Sadeer G. Al-Kindi, Houston Methodist Hospital, United States
Michael D. Shapiro, Wake Forest University School of Medicine, United States
Laurence Sperling, Emory University School of Medicine, United States
Salim S. Virani, Aga Khan UniversityFollow
Abdul Mannan Khan Minhas, Baylor College of Medicine, United States

Document Type

Commentary

Department

Office of the Provost; Cardiology

Abstract

Bempedoic acid has been shown to reduce major adverse cardiovascular outcomes in patients unable to take statins due to statin-associated side effects. Analysis of CLEAR Outcomes trial data reveals possible differences in baseline characteristics between the primary and secondary prevention subgroups. Further research is needed to optimize use of bempedoic acid and clarify its impact on cardiovascular outcomes in diverse patient populations.

Comments

Issue and pagination are not provided by the author/publisher.

Publication (Name of Journal)

American Journal of Preventive Cardiology

DOI

10.1016/j.ajpc.2024.100715

Recommended Citation

Mousavi, I., Nambi, V., Abushamat, L. A., Al-Kindi, S. G., Shapiro, M. D., Sperling, L., Virani, S. S., Minhas, A. K. (2024). Bempedoic acid in secondary prevention. American Journal of Preventive Cardiology, 19.
Available at: https://ecommons.aku.edu/provost_office/806